The group’s determination to conquer another rare epilepsy, tuberous sclerosis complex, looks questionable.
The third quarter will see important data for Travere, Radius and Sio Gene, among other small developers.
Important data releases are on the cards for Rhythm, Wave and Supernus, among others.
Sage gets a big endorsement for zuranolone, but the markets say it should have waited until it had a stronger negotiating position.
Marinus celebrates pivotal trial success with ganaxolone, but a quick approval could depend on lenient regulators.
The fragile X pipeline is strewn with failures, and crunch time is approaching for Zynerba’s cannabinoid.
In the wake of a clinical trial failure Marinus plays down oral ganaxolone, but investors are unimpressed.